Imaging of Malignant Lymphomas with F-18 FDG Coincidence Detection Positron Emission Tomography

Hwang, Kyu Ri; Park, Chan H.; Kim, Hugh C.; Kim, Hyunsoo; Yoon, Seok-Nam; Pai, Moonsun; Kim, Suzy

doi:10.1097/00003072-200010000-00008

Cited by 12 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(2) and (3), lymphoma [8,11], and melanoma [12,13]. FDG can also be used for staging and restaging and for therapeutic monitoring of breast cancer [14,15].…”

Section: / Fluorodeoxyglucose (Fdg) and The Glycolytic Metabolic Patmentioning

confidence: 99%

“…11 C-labelled methionine was then used to delineate tumour tissue. The exact mechanism of tumour uptake has not been elucidated and several studies have demonstrated the lack of specificity of 11 C-methionine for protein synthesis [45] and only showed that 11 C-methionine had a high affinity for tumours [46]. Some studies demonstrated that 11 C-methionine uptake was correlated with proliferation markers in patients with brain and lung carcinoma [47][48][49], but other studies failed to find any correlation in patients with head and neck and lung carcinoma [50,51].…”

Section: / Amino Acid Transport and Metabolismmentioning

confidence: 99%

See 1 more Smart Citation

Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging

Perek¹,

Nathalie²,

Denoyer³

et al. 2006

CMIR

View full text Add to dashboard Cite

Cancer develops as a result of an imbalance between cell proliferation and programmed cell death or apoptosis. Tumour cells are characterised by prolonged survival and uncontrolled proliferation. Tumour cells also acquire new functions, such as the capacity to migrate and colonise other organs by forming metastases. Cancer chemotherapy mainly acts by inducing apoptosis. However, resistance of human malignancies to multiple chemotherapeutic agents remains a major obstacle to the efficacy of treatment. Radiolabelled tracers used in Single Photon Emission Computed Tomography (SPECT) and more recently in Positron Emission Tomography (PET) screening in nuclear medicine have been developed to directly visualise in vivo biochemical and physiological parameters of tumour cells. These functional and molecular techniques have become an excellent research tool to study in vivo tumour biology. For instance, proliferation, apoptosis and multidrug resistance tracers have been complexed and studied on in vitro cellular models and several in vivo applications have been developed in the management of cancer patients. In this review, we focus on the radiotracers elaborated in the field of proliferation, apoptosis and MDR. We summarise the most recent studies in SPECT and PET imaging and their possible applications in oncology.

show abstract

“…(2) and (3), lymphoma [8,11], and melanoma [12,13]. FDG can also be used for staging and restaging and for therapeutic monitoring of breast cancer [14,15].…”

Section: / Fluorodeoxyglucose (Fdg) and The Glycolytic Metabolic Patmentioning

confidence: 99%

Section: / Amino Acid Transport and Metabolismmentioning

confidence: 99%

Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging

Perek¹,

Nathalie²,

Denoyer³

et al. 2006

CMIR

View full text Add to dashboard Cite

show abstract

“…7 Woolfenden et al developed and tested a mini-NaI͑Tl͒ probe that was passed through the channel of a bronchoscope to detect gamma arrays emitted by 57 Co-labeled-bleomycin preferentially absorbed in lung cancers. 8 Discovery of the excellent targeting of FDG to many cancers [9][10][11][12][13][14][15][16] has led to the proposed application of positronsensitive probes to guide surgeries. A significant complication incurred by the use of positron emitters for surgical guidance is the creation of 511 keV annihilation photons.…”

Section: Introductionmentioning

confidence: 99%

Endoprobe: A system for radionuclide‐guided endoscopy

Raylman

Srinivasan

2004

Medical Physics

View full text Add to dashboard Cite

Methods to guide the surgical treatment of cancer utilizing handheld beta-sensitive probes in conjunction with tumor-avid radiopharmaceuticals [such as 18F-fluorodeoxyglucose (FDG)] have previously been developed. These technologies could also potentially be used to assist in minimally invasive techniques for the diagnosis of cancer. The goal of this project is to develop and test a system for performing radionuclide-guided endoscopies. This system (called Endoprobe) has four major subsystems: beta detector, position tracker, endoscope, and user interface. The beta detection unit utilizes two miniaturized solid state detectors to preferentially detect beta particles. The position tracking system allows real-time monitoring of the unit's location. The beta detector and position tracking system's receiver are mounted on the tip of an endoscope. Information from the beta detector and tracking system, in addition to the video signal from the endoscope, are combined and presented to the user via a computer interface. The system was tested in a simulated search for radiotracer-avid areas of esophageal cancer. The search for esophageal cancer was chosen because this type of cancer is often diagnosed with endoscopic procedures and has been reported to have good affinity for FDG. Accumulations of FDG in the normal organs of the abdomen were simulated by an anthropomorphic torso phantom filled with the appropriate amounts of radioactivity. A 1.5- mm-thick gelatin film containing FDG was used to simulate radiotracer uptake in the lining of normal esophagus. Esophageal lesions (both benign and malignant) were simulated by thin disks of gelatin (diameters=3.5-12 mm) containing appropriate concentrations of FDG embedded in the gelatin film simulating normal esophagus. Endoprobe facilitated visual identification and examination of the simulated lesions. The position tracking system permitted the location of the Endoprobe tip to be monitored and plotted in real time on a previously acquired positron emission tomography-computed tomography (PET-CT) image of the phantom. The detection system successfully acquired estimates of the beta flux emitted from areas chosen by the user. Indeed, Endoprobe was able to assist in distinguishing simulated FDG-avid areas as small as 3.5 mm in diameter from normal esophagus (p value <0.025). In addition to FDG, Endoprobe can be used with other positron or electron-emitting radionuclides such as IC or 131I. The next phase of this project will focus on modification of the prototype to make it more suitable for clinical use.

show abstract

“…Células escamosas epiteliais e ninhos ou ilhas de células são observadas crescendo como entidades independentes dentro do tecido conjuntivo, muitas vezes sem ligação com o epitélio de superfície. As células da lesão podem destruir os vasos sangüíneos, e invadir o lúmen de veias ou vasos linfáticos (MAJNO;JORIS, 1996;NEVILLE et al, 2004 (HEMINGWAY et al, 1996;LIMA, 2002): utilizando um substrato com características ideais que incluem uma biodistribuição adequada para atingir o objetivo (o tecido alvo), com ausência de toxicidade ou efeitos secundários, é possível identificar e mapear a alteração presente em todo o corpo humano (BRAAMS et al, 1996;LIMA, 2002); o substrato de eleição 18 F-FDG da presente pesquisa tem uma alta captação em neoplasias malignas, segundo estudos in vitro, e esta captação está relacionada à avidez das células tumorais por este substrato, o que é proporcional à sua atividade metabólica (HANNAH, 2002); o tempo de meia-vida deste substrato (109 minutos) tem um papel decisivo em sua escolha, pois é suficiente para a realização do exame PET-CT sem que haja perda das informações necessárias, já que decorrido o período de meia-vida restará apenas cerca de 50% da radioatividade originalmente presente (CONTI;LILIENI;HAWLEY, 1996;GAMBHIR et al, 2001;KIM, 2000).…”

Section: Introductionunclassified

“…Quanto aos diferentes equipamentos existentes, podemos destacar a gama câmara com colimadores de alta energia, utilizadas na detecção de fótons de 511 keV (BEYER et al, 2004;BOCHER et al, 2001;VOGEL et al, 2004). Este aparelho detector de dupla coincidência tem algumas limitações, como imagens de baixa resolução, com uma qualidade inferior em comparação à obtida em aparelho PET dedicado (SHREVE et al, 1998), mesmo assim, pode ser uma razoável alternativa, como bem demonstrado na literatura (AK et al, 2001;HWANG et al, 2000).…”

Section: Introductionunclassified

Mapeamento topográfico metabólico de carcinomas espinocelulares de cabeça e pescoço utilizando a fusão de imagens 18 F-FDG PET - TC.

Santos¹

View full text Add to dashboard Cite

Imaging of Malignant Lymphomas with F-18 FDG Coincidence Detection Positron Emission Tomography

Abstract: Conclusions: For staging, FDG CoDe PET alone without attenuation correction is not sensitive enough to be used as an independent imaging method, especially for small abdominal lesions. However, it appears to be an accurate method for assessing residual disease and for patient follow-up.

Cited by 12 publications

References 34 publications

Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging

Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging

Endoprobe: A system for radionuclide‐guided endoscopy

Mapeamento topográfico metabólico de carcinomas espinocelulares de cabeça e pescoço utilizando a fusão de imagens 18 F-FDG PET - TC.

Contact Info

Product

Resources

About